The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed the day trading at $41.43 down -3.25% from the previous closing price of $42.82. In other words, the price has decreased by -$3.25 from its previous closing price. On the day, 1.98 million shares were traded. CRNX stock price reached its highest trading level at $42.49 during the session, while it also had its lowest trading level at $40.95.
Ratios:
For a better understanding of CRNX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.12 and its Current Ratio is at 15.12. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on July 10, 2025, initiated with a Neutral rating and assigned the stock a target price of $36.
On March 25, 2025, Stifel started tracking the stock assigning a Buy rating and target price of $60.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 03 ’25 when Pizzuti Dana sold 5,000 shares for $42.66 per share. The transaction valued at 213,312 led to the insider holds 66,270 shares of the business.
DANA PIZZUTI bought 5,000 shares of CRNX for $217,500 on Nov 03 ’25. On Oct 01 ’25, another insider, Pizzuti Dana, who serves as the Chief Med and Dev Officer of the company, sold 5,000 shares for $41.81 each. As a result, the insider received 209,050 and left with 66,270 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CRNX now has a Market Capitalization of 3931368960 and an Enterprise Value of 2888221952. For the stock, the TTM Price-to-Sale (P/S) ratio is 2569.52 while its Price-to-Book (P/B) ratio in mrq is 3.65. Its current Enterprise Value per Revenue stands at 1881.578 whereas that against EBITDA is -6.091.
Stock Price History:
The Beta on a monthly basis for CRNX is 0.21, which has changed by -0.21747077 over the last 52 weeks, in comparison to a change of 0.1476624 over the same period for the S&P500. Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is 2.76%, while the 200-Day Moving Average is calculated to be 21.59%.
Shares Statistics:
Over the past 3-months, CRNX traded about 1.56M shares per day on average, while over the past 10 days, CRNX traded about 1755150 shares per day. A total of 94.55M shares are outstanding, with a floating share count of 87.77M. Insiders hold about 7.50% of the company’s shares, while institutions hold 112.18% stake in the company. Shares short for CRNX as of 1761868800 were 13537482 with a Short Ratio of 8.68, compared to 1759190400 on 12384250. Therefore, it implies a Short% of Shares Outstanding of 13537482 and a Short% of Float of 16.209999.
Earnings Estimates
Its stock is currently analyzed by 12.0 different market analysts. The consensus estimate for the next quarter is -$1.4, with high estimates of -$1.19 and low estimates of -$1.7.
Analysts are recommending an EPS of between -$4.07 and -$5.19 for the fiscal current year, implying an average EPS of -$4.94. EPS for the following year is -$5.26, with 13.0 analysts recommending between -$3.94 and -$7.04.
Revenue Estimates
For the next quarter, 13 analysts are estimating revenue of $6.62M. There is a high estimate of $11.1M for the next quarter, whereas the lowest estimate is $5M.
A total of 14 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.54M, while the lowest revenue estimate was $2.5M, resulting in an average revenue estimate of $5.13M. In the same quarter a year ago, actual revenue was $1.04MBased on 14 analysts’ estimates, the company’s revenue will be $54.63M in the next fiscal year. The high estimate is $112.07M and the low estimate is $25.11M.
